Conference Coverage

Does reduced degradation of insulin by the liver cause type 2 diabetes?


 

EXPERT ANALYSIS FROM WCIRDC 2018

In some individuals, reduced degradation of insulin by the liver is the cause of type 2 diabetes mellitus.

of Cedars-Sinai Medical Center, Los Angeles Doug Brunk/MDedge News

Dr. Richard N. Bergman

That’s a hypothesis that Richard N. Bergman, PhD, and his colleagues are testing in his lab at the Sports Spectacular Diabetes and Obesity Wellness and Research Center at Cedars-Sinai Medical Center, Los Angeles.

“More than 50% of insulin secreted into the portal vein is degraded by the liver and never enters the systemic circulation,” Dr. Bergman said at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. “We have found that if you make an animal insulin resistant with a high fat diet, they degrade less of the insulin. Why is that? They deliver a higher fraction of the insulin into the systemic circulation. One of the answers is that the liver is a gateway for insulin delivery to the systemic circulation.” In fact, when he and his colleagues tested a population of normal dogs, they found wide variability in the ability of the liver to take up and degrade insulin (Diabetes. 2018 67[8]:1495-503).

“It ranged from 20% to 70%; I didn’t believe these data,” said Dr. Bergman, who is also chair in diabetes research at Cedars-Sinai. “We had to redo the study and the same thing was true. There’s a wide variation in what fraction of insulin that enters the liver is degraded. That led to the idea that this could be true in humans.”

Pages

Recommended Reading

U.S. death rates from chronic liver disease continue to rise
Journal of Clinical Outcomes Management
Should metabolic syndrome be renamed circadian syndrome?
Journal of Clinical Outcomes Management
Study investigates statin-diabetes link
Journal of Clinical Outcomes Management
New diabetes guidelines downgrade insulin as first-line injectable treatment
Journal of Clinical Outcomes Management
Active migraine in women linked to lower risk of developing T2DM
Journal of Clinical Outcomes Management
New risk-prediction model for diabetes under development
Journal of Clinical Outcomes Management
‘Payoff will be great’ if we can conquer childhood obesity, expert says
Journal of Clinical Outcomes Management
New diabetes drugs solidify their cardiovascular and renal benefits
Journal of Clinical Outcomes Management
Researchers exploring ways to mitigate aging’s impact on diabetes
Journal of Clinical Outcomes Management
Torrent Pharmaceuticals expands losartan recall
Journal of Clinical Outcomes Management